argenx SE (NASDAQ:ARGX) Shares Sold by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC cut its holdings in argenx SE (NASDAQ:ARGX) by 2.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,723 shares of the company’s stock after selling 49 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in argenx were worth $732,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its stake in argenx by 49.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock valued at $2,167,235,000 after acquiring an additional 1,830,651 shares during the period. Janus Henderson Group PLC boosted its position in argenx by 24.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock valued at $872,690,000 after purchasing an additional 439,889 shares during the period. Capital World Investors grew its stake in argenx by 37.0% during the 4th quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock worth $746,099,000 after buying an additional 530,181 shares during the last quarter. Avoro Capital Advisors LLC increased its position in argenx by 0.3% in the first quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock worth $487,609,000 after buying an additional 3,900 shares during the period. Finally, RTW Investments LP lifted its stake in argenx by 31.5% in the fourth quarter. RTW Investments LP now owns 667,195 shares of the company’s stock valued at $253,821,000 after buying an additional 160,000 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Wedbush upped their price target on shares of argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. JPMorgan Chase & Co. raised their price target on shares of argenx from $500.00 to $640.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Stifel Nicolaus lifted their price target on argenx from $485.00 to $500.00 and gave the company a “buy” rating in a report on Monday, June 24th. HC Wainwright increased their price objective on argenx from $504.00 to $533.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Finally, Guggenheim lifted their target price on argenx from $545.00 to $585.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Three investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $547.74.

argenx Trading Down 1.7 %

NASDAQ:ARGX opened at $519.76 on Wednesday. The company has a 50-day moving average of $514.88 and a 200-day moving average of $434.97. argenx SE has a twelve month low of $327.73 and a twelve month high of $554.74. The firm has a market cap of $30.89 billion, a price-to-earnings ratio of -91.83 and a beta of 0.62.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $1.34. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The firm had revenue of $489.43 million for the quarter, compared to analyst estimates of $436.66 million. During the same quarter in the previous year, the business posted ($1.69) earnings per share. On average, research analysts forecast that argenx SE will post -0.37 earnings per share for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.